Improved survival with early intensification: Combined results from The Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI

Leukemia

Volumn 12, Issue 7, 1998, Pages 1031-1036

  Richards, S ^a,e   Burrett, J ^a   Hann, I ^b   Chessells, J ^b   Hill, F ^c   Bailey, C ^d  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Childhood ALL; Intensification; Randomised

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MEDICAL RESEARCH; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; UNITED KINGDOM;

EID: 0031856144     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401065     Document Type: Article

References (24)

1. Medical Research Council. Improvement in treatment for children with acute lymphoblastic leukaemia. Lancet 1986; i: 408-411.
2. Niemeyer CM, Reiter A, Riehm H, Donnelly M, Gelber RD, Sallan SE. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: the Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols. Ann Oncol 1991; 2: 745-749.
3. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abromowitch M, Mirro J, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kahwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
4. Aur RJA, Simone J, Hustu HO, Vergosa MS. A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer 1972; 29: 381-391.
5. MRC Leukaemia Committee and the Working Party on Leukaemia in Childhood. Treatment of acute lymphoblastic leukaemia: effect of 'prophylactic' therapy against central nervous sytem leukaemia, Br Med J 1973; 2: 381-384.
6. Nesbit ME, Sather H, Robison LL, Donaldson M, Littman P, Ortega JA, Hammond GD. Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia. Cancer Res 1982; 42: 674-680.
7. Rowland JH, Glidewell OJ, Sibley RF, Holland JC, Tull R, Berman A, Brecher ML, Harris M, Glicksman AS, Forman E, Jones B, Cohen ME, Duffner PK, Freeman AI. Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia. J Clin Oncol 1984; 2: 1327-1335.
8. Freeman AI, Boyett JM, Glicksman AS, Brecher ML, Leventhal BG, Sinks LF, Holland JF. Intermediate-dose methotrexate vs cranial irradiation in childhood acute lymphoblastic leukemia: a 10-year follow-up. Med Fed Oncol 1997; 28: 98-107.
9. Rivera GK. Advances in therapy for childhood non-B-lymphoblastic leukaemia. Baill Clin Haematol 1994; 7: 273-298.
10. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet 1995; 345: 143-148.
11. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977; 35: 1-39.
12. Wheeler K, Chessells JM, Bailey CC, Richards SM. Treatment-related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child 1996; 74: 101-107.
13. Chessells J, Leiper A, Rogers D, Outcome following late marrow relapse in childhood acute lymphoblastic leukemia. J Clin Oncol 1984; 2: 1088-1091.
14. Rivera GK, Buchanan G, Boyett JM, Camitta B, Ochs J, Kalwinsky D, Amylon M, Vietti TJ, Crist WM. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. New Engl J Med 1986; 315: 273-278.
15. Buhrer C, Hartmann R, Fengler R, Dopfer R, Gadner H, Gerein V, Gobel U, Reiter A, Ritter J, Henze G. Superior prognosis in combined, compared to isolated, bone marrow relapse in salvage therapy of childhood acute lymphoblastic leukemia. Med Fed Oncol 1993; 21: 470-476.
16. Henze G, Fengler R, Reiter A, Ritter J, Riehm H. Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukaemia. Haematol Blood Trans 1990; 33: 483-488.
17. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Wette K, Gadner H, Reehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
18. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MI, Hammond GD. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol 1993; 11: 527-537.
19. Hudson MM, Jones D, Boyett J, Sharp GB, Pui C-H. Late mortality of long-term survivors of childhood cancer. J Clin Oncol 1997; 15: 2205-2213.
20. Rosso P, Terracini B, Fears TR, Jankovic M, Fossati Bellani F, Arrighini A, Carli M, Cordero di Montezemolo L, Garrè ML, Guazzelli C, Izzi G, Loiacono G, Mancini A, Tamaro P, Testi AM, Masera G, Haupt R. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy. Int J Cancer 1994; 59: 451-456.
21. Olsen JH, Garwicz S, Hertz H, Jonmundsson G, Langmark F, Lanning M, Lie SO, Moe PJ, Møller T, Sankila R, Tulinius H for the Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. Second malignant neoplasms after cancer in childhood or adolescence. Br Med J 1993; 307: 1030-1036.
22. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl J Med 1991; 324: 808-815.
23. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival vs late cardiotoxicity. J Clin Oncol 1997; 15: 61-68.
24. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997; 15: 1544-1552.